Drug Trial Radar · NCT05558007
Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
72
Planned (sponsor's estimate)
Start
Nov 22, 2023
Primary completion
Dec 31, 2024
Study completion Jan 31, 2025
Sponsor
- Lead sponsor
- Biozeus Biopharmaceutical S.A.Industry
- Sponsor type
- Industry
- First posted
- Sep 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.
Conditions
- Erectile Dysfunction Following Radical Prostatectomy
- Erectile Dysfunction
- Prostate Cancer
- Radical Prostatectomy
Interventions
Tadalafil 5mgDrug
Daily oral administration of tadalafil 5mg
BZ371ADrug
Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
Oral PlaceboDrug
Oral administration of a placebo pill
Topical PlaceboDrug
Topical application of 1.5 mL of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Assisted Erectile FunctionTime frame: From up to 30 days before Baseline, Baseline, 30 days, 60 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Urológica
Belo Horizonte, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.